Skip to main content
Retour
Watch Compare

CHINA PHARMA HOLDINGS, INC.

Qualité des données : 100%
CPHI
NYSE Manufacturing Chemicals
0,66 €
▲ 0,04 € (5,65%)
Cap. Boursière: 3,29 M
Prix
0,66 €
Cap. Boursière
3,29 M
Fourchette du Jour
0,53 € — 0,66 €
Fourchette 52 Semaines
0,50 € — 2,60 €
Volume
13 178
Ouverture 0,53 €
Moyenne 50J / 200J
0,70 €
6,48% below
Moyenne 50J / 200J
1,40 €
53,30% below

Quick Summary

Points Clés

Revenue declined -19,03% annually over 5 years
Debt/Equity of 0,17 — conservative balance sheet
Generating 88 937,0 in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10,54%
Capital efficient — spends only 1,43% of revenue on capex

Croissance

Revenue Growth (5Y)
-19,03%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)-8,49%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-43,15%
Au-dessus de la moyenne du secteur (-53,47%)
ROIC-24,94%
Net Margin-76,91%
Op. Margin-78,16%

Sécurité

Debt / Equity
0,17
En dessous de la moyenne du secteur (0,31)
Current Ratio0,35
Interest Coverage-118,77

Valorisation

PE (TTM)
-1,03
Au-dessus de la moyenne du secteur (-1,47)
P/B Ratio0,40
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -1,0 -1,5
P/B 0,4 1,6
ROE % -43,2 -53,5
Net Margin % -76,9 -41,5
Rev Growth 5Y % -19,0 1,8
D/E 0,2 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -8,49% Revenue Growth (3Y) -23,12%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -19,03% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4,14 M Net Income (TTM) -3,19 M
ROE -43,15% ROA -21,56%
Gross Margin -3,18% Operating Margin -78,16%
Net Margin -76,91% Free Cash Flow (TTM) 88 937,0
ROIC -24,94% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,17 Current Ratio 0,35
Interest Coverage -118,77 Asset Turnover 0,28
Working Capital -4,29 M Tangible Book Value -461 039
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,03 Forward P/E N/A
P/B Ratio 0,40 P/S Ratio 0,79
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 2,70%
Market Cap 3,29 M Enterprise Value 4,44 M
Per Share
EPS (Diluted TTM) -0,74 Revenue / Share 0,83
FCF / Share 0,02 OCF / Share 0,03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,43% FCF Conversion -2,79%
SBC-Adj. FCF N/A Growth Momentum 10,54

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,14 M 4,53 M 7,01 M 8,10 M 9,64 M
Net Income -3,19 M -4,74 M -3,08 M -3,97 M -3,40 M
EPS (Diluted) -0,74 -0,27 -0,91 -0,76 —
Gross Profit -131 950,0 -1,99 M -281 085,0 -493 916,0 349 270,0
Operating Income -3,24 M -4,59 M -2,75 M -3,55 M -2,86 M
EBITDA — — — — —
R&D Expenses 280 901,0 283 942,0 240 080,0 185 858,0 318 964,0
SG&A Expenses — — — — —
D&A 1,50 M 2,62 M 2,75 M 2,70 M 3,09 M
Interest Expense 27 272,0 27 353,0 333 600,0 434 619,0 542 001,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 31,00 M 14,89 M 16,47 M 17,78 M 22,65 M
Total Liabilities 8,26 M 7,14 M 9,01 M 13,49 M 16,63 M
Shareholders' Equity 22,74 M 7,75 M 7,45 M 4,29 M 6,02 M
Total Debt 1,44 M 1,14 M — — —
Cash & Equivalents 345 112,0 600 000,0 1,42 M 2,03 M 4,86 M
Current Assets 2,35 M 3,27 M 6,00 M 5,96 M 9,09 M
Current Liabilities 7,40 M 5,02 M 6,82 M 12,74 M 10,51 M